KAPA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kairos Pharma Ltd (KAPA) is not a good buy for a beginner investor with a long-term strategy at this moment. The technical indicators show a bearish trend, and there are no significant positive catalysts or trading signals. The company's financial performance is weak, with negative net income and declining EPS. Additionally, there is no recent news or trading activity to suggest a potential upside.
The technical indicators show a bearish trend. The MACD is below zero and negatively expanding, the RSI is neutral at 25.475, and moving averages indicate a bearish setup (SMA_200 > SMA_20 > SMA_5). The stock is trading below its key pivot level of 0.638, with support at 0.6 and resistance at 0.676.
NULL identified. There is no recent news, no significant hedge fund or insider activity, and no recent congress trading data.
and declining EPS (-30% YoY). Technical indicators suggest a bearish trend.
In Q3 2025, the company reported zero revenue growth, a net income loss of -$1,398,000 (up 33.52% YoY), and an EPS decline of -30% YoY. Gross margin remains at 0.
No analyst rating or price target data available.
